02.02.2010 – 19:06
EANS-Voting Rights: Epigenomics AG
Release of a voting rights announcement
according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim
of a Europe-wide distribution
-------------------------------------------------------------------------------- Notification of voting rights transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------
Person/company obliged to make the notification:
-----------------------------------
Name: Federated Investors Inc. Place: Pittsburgh, PA State: USA
Company data: -----------------------
Name: Epigenomics AG Address: Kleine Präsidentenstraße 1, 10178 Berlin Place: Berlin State: Deutschland
Voting Rights: Release of a Voting Rights Notification (§§ 21 et seq. WpHG) in Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide Distribution
Issuer:
Epigenomics AG Kleine Präsidentenstr. 1 10178 Berlin Germany
Voting Rights Notification:
On 2 February 2010, Federated Investors Inc., Pittsburgh, PA, USA, in the name and on behalf of the Federated Kaufmann Fund, Pittsburgh, PA, USA, made the following notifications regarding the holding of voting rights held in Epigenomics AG pursuant to § 21 para. 1 WpHG:
On 28 January 2010 Federated Kaufmann Fund fell below the 15 per cent thresholds of § 21 para. 1 WpHG and held at this date 14.983 per cent (i.e. 4,404,350 shares with voting rights of the 29,394,724 shares outstanding) in Epigenomics AG.
Federated Investors Inc., is the parent company of F II Holdings Inc., Pittsburgh, PA, USA, which in turn is the parent company of Federated Equity Management Company of Pennsylvania. Federated Equity Management Company of Pennsylvania, an investment adviser registered in the United States under the Investment Company Act of 1940, acts as Investment Adviser to the Federated Kaufmann Fund, a Massachusetts Business Trust and Investment Company, as that term is defined under the Investment Company Act of 1940.
Date of release: 2 February 2010
Epigenomics AG The Executive Board
Contact:
Epigenomics AG Dr. Achim Plum Senior Vice President Corporate Development Tel.: +49 (0)30 24345 368 Fax: +49 (0)30 24345 555 Email: achim.plum@epigenomics.com
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade
Kontaktdaten anzeigen/ausblenden
Further inquiry note:
Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade
Original content of: Epigenomics AG, transmitted by news aktuell